article thumbnail

Mechoulam on the Future of Cannabinoid Research

Project CBD

I was fortunate to cross paths with Raphael Mechoulam, “the father of cannabis research,” at several science conferences over the years. The most memorable occasion was the 22nd annual meeting of the International Cannabinoid Research Society (ICRS) in Freiburg, Germany, in July 2012.

article thumbnail

The Top Medical Cannabis Research of 2017

MGC Pharma

The Top Medical Cannabis Research of 2017 A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Here’s what you need to know about cannabis research

The Cannigma

There’s no doubt that the amount of information that is available about cannabis is at an all-time high – in 2020 alone, over 3,500 scientific articles were published on the topic. Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects.

article thumbnail

The National Institute on Drug Abuse (NIDA) Funding Research On Differing Legal Cannabis Regulatory Models

Cannabis Law Report

The National Institute on Drug Abuse (NIDA) is renewing its push to promote federally funded research into marijuana as more states enact reform—specifically expressing interest in studies on differing cannabis regulatory models that are in place across the country. Read full report.

article thumbnail

Dyskinesia Drugs In Development Pipeline Report 2021 – ResearchAndMarkets.com

Cannabis Law Report

DUBLIN–(BUSINESS WIRE)–The “Dyskinesia (Central Nervous System) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering. Dyskinesia – Drugs In Development, 2021, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape. Appendix.

article thumbnail

Heritage Cannabis Enters Exclusive Partnership to Commercialize Avicanna’s Evidence-Based Topical Products through Heritage’s Medical Opticann Brands

Cannabis Law Report

Exclusive licensing of certain of Avicanna’s advanced and evidence-based CBD topical products including its deep tissue and skin care formulations. Avicanna”), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products. They are a great strategic fit.

Topical 75
article thumbnail

cbdMD Therapeutics Releases Research Plan

Cannabis Law Report

(NYSE American: YCBD, YCBDpA), one of the leading, and most highly trusted and recognized CBD companies, announced today that its recently formed division, cbdMD Therapeutics, has initiated talks with one of the leading US cannabinoid research institutes, to identify novel cannabinoids for therapeutic use. About cbdMD, Inc. cbdMD, Inc.